(MedPage Today) — CHICAGO — Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients helped delay serious outcomes in the ZENITH trial. Among 172 patients, the drug reduced the… Source link : https://www.medpagetoday.com/meetingcoverage/acc/114911 Author : Publish date : 2025-04-01 14:58:00 Copyright for syndicated content belongs to the linked Source.
The post Sotatercept Helps the Sickest Patients With Pulmonary Arterial Hypertension first appeared on News Health.
Author : News Health
Publish date : 2025-04-01 14:58:00
Copyright for syndicated content belongs to the linked Source.